World TB Day is an opportunity to raise awareness about the burden of tuberculosis worldwide and the status of TB prevention and control efforts. It is also an opportunity to mobilize political and social commitment for further progress.

HIV and TB co-infection makes up one-third of all TB-related deaths worldwide. TB is a growing threat to people who use drugs, particularly when set against the backdrop of high vulnerability to, and prevalence of, HIV.

EMA's response to TB CAB letter regarding the filing of the drugs delamanid and bedaquiline for market approval.

The new FY 2011/12 Report to Congress on TB highlights key programmatic achievements and collaboration of the different U.S. Government agencies involved in global TB programs, bringing comparative expertise to address the many challenges of TB.

The guide offers clear, practical advice on how to manage the patients who have multidrug-resistant tuberculosis.

1000 days to achieve international targets of 50% reductions in TB mortality and TB/HIV deaths by 2015

A new two-drug combination of rifapentine and moxifloxacin can allow tuberculosis treatment to be taken once-weekly during the four-month continuation phase.

Research and access required to achieve zero deaths, new infections, and suffering

Health Ministers from several African countries and leaders of international agencies are meeting in Swaziland tomorrow where they will launch a fresh offensive against tuberculosis and TB among people with HIV.

Open letter to the European Medicines Agency regarding the filing of the drugs delamanid and bedaquiline for market approval.